Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced the initiation of a Phase II clinical...
Haixi Pharmaceuticals
Fujian Haixi Pharmaceuticals Files for Hong Kong IPO
China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial...